Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.
$31.00+6.90%
报价 2026-11-06
市值
$231.8M
EV
$113.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -9.2%
$11.80$34.13
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SRZNSurrozen, Inc. | $231.8M | +6.9% | +178.3% | 99.4% | – | – | – | |
| IMMXImmix Biopharma, Inc. | $668.2M | +11.9% | +72.9% | 0% | – | – | – | |
| IRDOpus Genetics, Inc. | $347.8M | +4.4% | -1.5% | 99.9% | – | – | – | |
| AGENAgenus Inc. | $322.9M | +11.0% | +26.2% | 76.5% | 9.7x | 3.4x | – | |
| GLSIGreenwich LifeSciences, Inc. | $222.7M | +3.5% | – | 0% | – | – | – | |
| SEERSeer, Inc. | $90.3M | -4.1% | -4.1% | 47% | – | – | – | |
| CGTXCognition Therapeutics, Inc. | $65.3M | +8.1% | +14.4% | 0% | – | – | – | |
| TILInstil Bio, Inc. | $46.3M | -2.3% | +2.6% | 0% | – | – | – | |
| TVGNTevogen Bio Holdings Inc. | $23.3M | +0.5% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +8.5% | 0% | 9.7x | 3.4x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。